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ABSTRACT 
Mama Decoction® (MD) is an aqueous antimalarial herbal preparation obtained from combination of Mangifera indica, Alstonia 
boonei, Morinda lucida and Azadirachta indica leaves with each component plant reported to have anti-plasmodial activity. 
Management of plasmodial infections is usually accompanied by co-administration of antipyretic and analgesic agent with 
paracetamol being the most common. Therefore, the study investigated the biological implications of co-administration of MD 
with paracetamol (PA) in in-vivo anti-plasmodial model in mice. The anti-plasmodial activity of MD (1mL/kg bw), chloroquine 
phosphate (Cq) (10mg/kg bw) alone and co-administration with PA (15mg/kg bw) (PMD and PCq) were evaluated by oral 
administration using established malaria infection test (Rane’s test). Chloroquine phosphate and distilled water were used as  
positive and negative controls respectively. Haematological analysis and histopathological evaluation of the liver and kidney 
were done using standard procedures. Reduction in parasitaemia at day 4 of treatment with MD, PMD, Cq, PCq were 34.80%, 
42.36%, 86.84% and 77.25% respectively. PA significantly reduce anti-plasmodial effect of Cq (p=0.0239), while the enhanced 
activity on MD was not significant (p=0.3090). Significant reduction (p=0.0027) in PCV and Hb in MD, PA and untreated 
parasitized group were observed. Hepatotoxicity were observed in parasitized treated and non-treated groups with more effect 
by co-administration with PA. Different levels of renal tubular epithelial necrosis were observed in the parasitized untreated and 
Cq groups. The results confirmed anti-plasmodial activity of MD, which though non-significantly reduced by its co-
administration with paracetamol has hepatotoxic potential 
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INTRODUCTION 
 
The use of herbal medicinal products is on the increase 
worldwide and the practice of co-administration of herbal 
medicinal products with western medicines is raising a public 
health concern globally and most importantly in the 
developing countries (Bamidele et al., 2018). This growing 
increase in the practice of co-administration of herbal 
medicinal products with western medicines is enhanced by the 
availability of these products as food/dietary supplements 
without prescription with little or no regulation. However, the 
fact that natural products are not evaluated for possible 
interactions with conventional drugs has raised a growing 
concern about the possible interactions of these conventional 
drugs with herbal medicinal products (Gardiner, et al., 2008).  
 Over the years, several clinically relevant herb-drug 
interactions have been reported, resulting in altered 
bioavailability, pharmacological activity, toxicity/adverse 
reactions that are sometimes life threatening (Elvin-Lewis, 
2001; Mohamed and Frye, 2012; Alzubaidi, and Hussain, 
2015; Obiageri, 2018). For instance, ginseng was reported to 
induce mania when concurrently administered with 
phenelzine (Mustapha et al., 1996), while an enhanced 
hypoglycemic effect was reported when chlorpropamide was 
taken with meal containing garlic and Mormodica charantia 
in the treatment of type 2 diabetes (Aslam and Stockley, 
1979). For gingko biloba, haemorhage associated with 
concomitant use with aspirin, warfarin and 
acetaminophen/ergotamine caffeine preparation have been 
documented (Rowin and Lewis, 1996; Gianni and Dreitlein, 
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1998). Also, the leaves of Carica papaya (Pawpaw) with 
antimalarial activity was reported to antagonize antimalarial 
properties of artesunic acid in Plasmodium berghei-infected 
mice (Onaku, 2011). However, synergistic herb-drug 
interactions were reported for Vernonia amygdalina with 
chloroquine (Nandakumar et al.,2006) and curcumin (isolated 
from Curcuma longa) with artemisinin (Iwalokun, 2008) 
when co-administered respectively. Similarly, Adepiti et al., 
(2016) reported a total clearance of parasitaemia when Mama 
Decoction® (MD) was co-administered with amodiaquine in 
CQ-resistant Plasmodium berghei infected mice at their 
therapeutic doses. 
 Mama Decoction® (MD) is an aqueous antimalarial herbal 
preparation obtained from Mangifera indica, Alstonia boonei, 
Morinda lucida and Azadirachta indica leaves with each 
component plant reported to have anti-plasmodial activity 
(Awe et al., 1998; Isah et al., 2003). Also, antimalarial 
constituents of A. indica and M. lucida leaves have been 
isolated (Khalid et al., 1989; Cimanga et al., 2006). A 
significant suppressive and about 50% curative activities of 
MD was reported by Odediran et al., (2014), while previous 
study on sub-chronic toxicity study of MD reported normal 
kidney and liver tissues morphology in non-parasitized 
animals (Akanmu et al., 2013). 
  The symptom of malaria is usually accompanied by 
pyrexia and analgesia, thus, management of plasmodial 
infections is most times accompanied by co-administration 
with antipyretic and analgesic agents with paracetamol being 
the most common analgesic agent. In view of the reported 
safety issues accompanying co-administration of herbal 
products and orthodox drug compounds, there is the need to 
regularly evaluate such co-administration, hence, this study 
reported the safety profile and possible pharmacological 
implications of co-administering MD with paracetamol using 
in-vivo anti-plasmodial model. 
 
MATERIALS AND METHODS 
 
Reagents: Giemsa stain, glacial acetic acid, methanol, 
formalin, chloroform (Aldrich Chemical Company Ltd, 
England) and paracetamol powder. All other chemicals were 
of analytical grade.  
 
Procurement of Mama Decoction® and paracetamol 
powder: Mama Decoction® (MD) with batch number 
FP15001 and Paracetamol powder (Tianju Bofa 
Pharmaceutical Corporation Ltd, India) were obtained from 
Drug Research and Production Unit (DRPU), Faculty of 
Pharmacy, Obafemi Awolowo University, Ile-Ife, Osun State, 
Nigeria.  
 
Identification and assay of paracetamol powder: 
Ultraviolet spectroscopic analysis, melting point and chemical 
content determination for paracetamol powder were carried 
out using official method (BP 2013).  
 
Experimental animals: Thirty-five (35) healthy Swiss albino 
mice of both sexes weighing 20-26g were obtained from the 
animal house of the Faculty of Pharmacy, Obafemi Awolowo 
University, Ile-Ife, Nigeria. The animals were housed under a 
12-h light/dark cycle with free access to water and commercial 
food pellets (Vital Feed Nig. Ltd, Jos, Nigeria). They were 
acclimatized for about two weeks before use and were used in 
accordance with the National Institute of Health (NIH) “Guide 
for the Care and Use of Laboratory Animals” 1985. 
 
Drug and herbal product administration: Chloroquine 
phosphate (reference antimalarial drug) was administered at 
10mg/kg bw of chloroquine base once daily for two (2) days 
and 5mg/kg bw on day 3. Mama Decoction® was administered 
at 1mL/kg bw 12 hourly for four days (based on the dosage 
instruction) and paracetamol (15mg/kg bw) was administered 
8 hourly for three days. The dosages were based on the 
standard dosages for the three preparations. All the drugs were 
administered by oral gavage. 
 
Parasite strain: Chloroquine-sensitive Plasmodium berghei 
NK65 strain was obtained from the Department of Chemistry, 
Faculty of Science, OAU, Ile-Ife, Nigeria. The parasites were 
maintained in continuous blood passage in mice. The 
parasitized blood donor mice with high parasitaemia was used 
for inoculation by first anaesthetizing the mouse with 
chloroform, and through cardiac puncture the blood was 
collected using sterile heparinized bottles. The percentage 
parasitaemia was determined. Appropriate volume of blood 
was then obtained from the donor mouse and diluted with 
sterile normal saline so that the final inoculum (0.2mL) for 
each mouse contains 107 parasitized red blood cells. 
 
Rane’s curative antiplasmodial test: The curative effect of 
MD and its interaction with paracetamol was assessed by the 
method described by Ryley and Peters (1970). Thirty mice 
were inoculated intraperitoneally, each with 0.2mL standard 
inoculum of infected blood containing 107 CQ-sensitive 
Plasmodium berghei NK 65 parasitized red blood cells on the 
first day. After the parasitaemia was established in the blood 
(72 hours later), the mice were randomly divided into six (6) 
groups (n=5, both sexes) per group. The infected untreated 
group (UM) was the negative control and the seventh group 
was uninfected healthy (HM) untreated group. Both groups 
were treated with 0.2mL distilled water. On the other hand, 
infected groups were treated with chloroquine (Cq), 
paracetamol (PA), MD, PA co-administered with MD (PMD), 
and PA co-administered with Cq (PCq) respectively. The 
administration was done by oral gavage. Giemsa stained thin 
blood smears prepared from tail snips were used to monitor 
the level of parasitaemia on days 1, 2, 3, 4, 7 and 9 by 
microscopic examination. The parasitaemia was determined 
by obtaining the percentage of the ratio of parasitized RBC to 
the total number of RBC. Percentage reduction (or parasite 
clearance) was calculated as 100× [(A–B)/A], where A is the 
average parasitemia of day 0 prior to treatments and B is the 
average parasitemia on days 1, 2, 3, 4, 7 and 9. 
 
Haematological and biochemical analyses: At the end of the 
experiment, the animals were anaesthetized with chloroform 
and blood was obtained using cardiac puncture technique. 
Blood (5ml) each was collected into the pre-labelled 
ethylenediaminetetraacetic acid (EDTA) sample bottles, 
which were gently rolled to allow the blood to mix thoroughly 
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with the anticoagulant. The blood was evaluated for packed 
cell volume (PCV), haemoglobin level (Hb), WBC, platelets 
count, neutrophils and lymphocytes counts using standard 
methods (Baker, et al., 1998). 
 
Histopathology: The liver and the kidney were removed, 
stored in sample bottles containing 10% buffered formalin 
solution and preserved for histopathological evaluation using 
standard procedures (Soujanya, et al., 2013). 
 
Statistical analysis 
Analysis of variance (one-way and two-way ANOVA) and 
Chi-square test were used for the various experimental test 
conditions at p<0.05 compared with their controls. The post 
hoc test of Dunnett`s Multiple Comparison Test (DMC) was 




Identification and assay of paracetamol powder: 
Ultraviolet spectroscopic analysis for paracetamol powder 
showed maximum absorption at 248.34nm while its melting 
point was 168o-170oC. The assay of paracetamol powder in 
triplicate gave a chemical content of 99.9%w/w which 
correspond to 99-101% of the official method (BP 2013). 
 
Antiplasmodial activity: The parasitaemia level was reduced 
by the administration of MD, PMD, Cq and PCq while 
increase was observed with UM and PA groups (Figure 1). 
The reduction in parasitaemia at day 4 of treatment were 
34.80%, 42.36%, 86.84% and 77.25% for MD, PMD, Cq and 
PCq respectively (Figure 2). The increase in percentage 
reduction of parasitaemia with co-administration of PA with 
MD (PMD) was not significant (p=0.3090). However, a 
significance decrease (p=0.0239) in percentage reduction in 
parasitaemia was observed when PA was co-administered 
with Cq (PCq) (Figure 2). Antiplasmodial activity of MD and 
PMD groups were significantly lower than Cq and PCq 
(Figure 2).  
 
 
Figure 1  
Percentage (%) parasitaemia of the parasitized mice at different days 
of drugs and Mama Decoction® (MD) treatments (day 0, 1, 2, 3, 4, 7 
and 9 of drugs and Mama Decoction administration). Data are 
expressed as Mean ± S.E.M, (p<0.05). 
 
 
Figure 2  
Percentage (%) reduction in parasitaemia level of the parasitized mice 
at different days of drugs and Mama Decoction® (MD) treatments (day 
1, 2, 3 and 4 of drugs and Mama Decoction® (MD) administration). 




Table 1  
Effects of MD, PA, Cq and their combinations on haematological parameters of parasitized and non-parasitized mice day 6 post treatments 
Code PCV (%) HB (g/dL)  WBC (×109/L) Platelet (×109/L) NEU (%) LYM (%) 
HM 28.0 ± 2.26 9.32 ± 0.75 7.54 ± 1.20 183 ± 6.98 24.40 ±2.66 75.60 ±2.66 
UM 6.67 ± 1.67a  2.23 ± 0.53 a   12.53 ± 3.47 148 ± 2.00 22.33 ±2.96 77.67 ±2.96 
PA 8.00 ± 2.16 a   2.68 ± 0.71 a   13.50 ± 2.78 157 ± 8.48 20.75 ±5.02 79.25 ±5.02 
MD 10.00 ±2.08 a   3.33 ± 0.69 a 11.50 ± 0.71 175 ± 18.58 41.67 ±9.17 58.33 ±9.17 
PMD 17.50 ±2.50 5.85 ± 2.15 13.80 ± 1.80 182 ± 21.00 36.00 ±6.00 63.50 ±6.50 
Cq 22.33 ±2.60 7.43 ± 0.87 9.03 ± 2.41 85 ± 36.20 a, b 17.33 ±4.63 82.33 ±4.91b 
PCq 18.0 ± 1.47 6.00 ± 0.48 9.28 ± 0.75 131 ± 9.51 21.00 ±4.92 79.00 ±4.92 
Data are expressed as mean ± S.E.M, (p<0.05).  
a= statistically significant when compared with the control 
b= statistically significant when Cq was compared with MD. 
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Figure 3  
PCV (%) and Hb (g/dL) of the parasitized and non-parasitized mice day 9 of treatments with PA, Cq, PCq, MD and PMD. Data 
are expressed as mean ± S.E.M, (p<0.05)  
 





Histopathological evaluation: Histopathological analyses 
showed that kidney tissues showed renal degeneration in UM 
and Cq groups (Plate 2) and the liver tissues with varying 
degrees of hepatocytes damage in all the parasitized treated 






The symptoms of malaria are usually accompanied by pyrexia 
and analgesia; hence its treatment usually involves the use of 
antipyretic and analgesic agents alongside antimalarial drugs. 
A previous study reported the use of PA with herbal products 
including MD in 50% of the respondents (Bamidele et al., 
2018). This is due to the ease of availability and effectiveness 
of PA in the management of pyrexia and pain associated with 
malaria. This study on the implication of co-administration of 
MD and PA focused on pharmacodynamics, haematological 
and histopathological assessment. 
 A significant reduction in parasitaemia was observed with 
Cq and MD (p< 0.0001) and their co-administration with PA, 
however, the parasitaemia reduction for Cq was significantly 
higher than MD (p< 0.0001, Figure 2). The increase in 
parasitaemia observed in PA corroborates the fact that 
paracetamol possess no anti-plasmodial activity.  
Plate 1  
Photomicrograph sections of the mice 
kidney tissues showing normal 
morphology in healthy non-parasitized 
(HM), renal tubular epithelial necrosis 
in untreated parasitized (UM), normal 
morphology in parasitized PA and MD, 
and moderate degeneration of renal 
tubular epithelium in parasitized Cq.   
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Plate 2  
Photomicrograph sections of the mice liver tissues showing normal morphology in healthy non-parasitized (HM), diffuse 
hepatocellular degeneration (swelling) and formation of megalocytes in untreated parasitized (UM), perivasculitis, centrilobular 
hepatocellular degeneration and necrosis with kupffer hyperplasia in PA, focal necrotizing hepatitis with diffuse kupffer 
hyperplasia and parasitic section in Cq, hepatocellular degeneration and necrosis in PCq, centrilobular degeneration and necrosis 
of hepatocytes with a few inflammatory cells in MD, and kupffer hyperplasia and hepatocellular necrosis in PMD 
 
The anti-plasmodial activity of MD obtained in this study 
though lower than Cq justifies its use in the treatment of 
malaria, which corroborates the report by Adepiti et al., (2014) 
and Odediran et al., (2014). Increased parasitaemia reduction 
when PA was co-administered with MD (PMD) was not 
statistically significant (p=0.3090), however, PA significantly 
decrease (p=0.0239) parasitaemia reduction of Cq (PCq) 
(Figure 2). This indicates that while paracetamol may not 
affect the efficacy of MD, it could compromise the 
effectiveness of Cq. 
 Meanwhile, there was no total clearance in parasitaemia as 
at the 4th day of administration for the completion of 
treatments, while a gradual increase in parasitaemia was 
observed at days 7 and 9 (days 3 and 5 after completion of 
drug and herbal treatments) (Figure 1). This indicates 
recrudescence which was higher for MD than Cq (p<0.05), 
with paracetamol not having any effect on the rate of 
recrudescence of PMD. 
  The anti-plasmodial activity of MD could be due to the 
presence of saponins and anthraquinones which have been 
associated with anti-plasmodial activity of plants (Philipson 
and Wright,1991; Christensen and Kharazmi, 2001). 
Behavioral assessment observed that the groups administered 
with paracetamol were more active indicating the 
pharmacodynamics activity of PA in militating against pain 
associated with plasmodial infection.  
 Haematological parameters are important indices of the 
physiological and pathological status for both animals and 
humans (Obianime and Aprioku, 2011). The findings in this 
study observed a significant decrease (p= 0.0027) in PCV and 
Hb in the treated parasitized groups (MD and PA) and the 
untreated parasitized group (UM) as compared to the healthy 
control group (HM) (Table 1). This decrease in PCV and Hb 
of the parasitized mice may be due to the haemolytic effect of 
Plasmodium berghei (Chinchilla et al., 1998) and not the 
drug/herb products. This could be justified by a previous 
report of insignificant reduction in PCV, RBC and Hb in 
healthy albino rats treated with MD (Bamidele et al., 2018). 
However, treatment with Cq, PCq and PMD had no significant 
effect (p>0.05) on PCV and Hb (Table 1).  
 Similary, the difference observed in PCV and Hb of Cq 
and MD, Cq and PCq, PCq and PMD, MD and PMD were 
equally not significant (p>0.05). This could be related to their 
extent of reducing parasitaemia corresponding to higher 
percentage reduction in Cq (86.84%), PCq (77.25%) and PMD 
(42.36%) compared to MD with 34.80% (Figure 2). Hence, it 
can be deduced that reduction in PCV and Hb was as a result 
of haemolysis of red blood cell (RBC) caused either by 
parasite multiplication or by spleen reticuloendotelial cell 
action (Chinchilla et al., 1998). This decrease may also be due 
to multiple causes, of which repeated haemolysis of infected 
red cells takes preference.  
 On the other hand, other haematological parameters 
showed no significant difference (p>0.05) when compared 
with HM except for Cq with significant reduction (p= 0.0053) 
and increase (p= 0.0023) in platelet and lymphocytes counts 
respectively. However, the difference in platelet counts 
between Cq and PCq was not significant. Platelet helps in 
blood clotting to prevent wound infections, and a low platelet 
count could expose the rats to various infections. Low platelet 
counts cause clot retraction to be deficient leading to poor 
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to coagulate effectively. Thus, the decrease in platelet counts 
in Cq group is of clinical significance. However, low platelet 
counts have been reported in plasmodium infected people 
(Kotepui et al., 2014; Tarig, et al., 2016). 
 The hepatocytes in healthy group were relatively intact, 
however, varied degrees of hepatoxicities in the parasitized 
treated groups could be attributed to the destructive effect of 
parasitaemia on the liver tissues (Viriyavejakul, et al., 2014; 
Onyesom and Onyemakonor, 2011). Also, the kidney tissues 
showed different levels of renal degeneration in UM and Cq 
(Plate 1) and varying degrees of liver damage (hepatotoxicity) 
in the parasitized groups. A previous study reported normal 
morphology for liver and kidney tissues in non-parasitized 
animal treated with MD in sub-chronic toxicity study 
(Akanmu et al., 2013), thus, the observed hepatocytes damage 
is most likely not as a result of MD treatment. However, it can 
be deduced from this study that the co-administration of MD 
with PA (PMD) at normal dose is accompanied by higher level 
of hepatotoxicity when compared with MD alone compared to 
what was obtained with PA alone. 
 In conclusion, the results confirmed the anti-plasmodial 
activity of Mama Decoction® (MD) which was significantly 
lower than chloroquine. However, co-administration of 
paracetamol with Mama Decoction® resulted in a slight 
enhancement of anti-plasmodial effect which may not be 
clinically significant. Furthermore, co-administration of 
Mama Decoction® with paracetamol should be with caution in 
view of the observed hepatotoxicity. 
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